Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include TipRanks, GuruFocus, Yahoo and Baton Rouge Business Report. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 132d ago.
Quick answers
Why is "Eli Lilly, Regeneron among first companies selected for FDA initiative to speed " trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (14)
- FDA selects Lilly, Regeneron, Fujifilm, 4 others for PreCheck Pilot Program Fierce Pharma · 132d ago
- FDA PreCheck pilot program selects Eli Lilly, Regeneron qz.com · 132d ago
- Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme Yahoo Finance · 132d ago
- FDA picks Eli Lilly and Regeneron for program to speed up domestic drug factory reviews qz.com · 132d ago
- FDA Picks 7 Pharma Companies for Manufacturing Pilot Powder & Bulk Solids · 132d ago
- Kriya Selected for FDA PreCheck Pilot Program BioSpace · 132d ago
- Eli Lilly (LLY) Joins FDA PreCheck Pilot Program to Enhance Drug Manufacturing GuruFocus · 132d ago
- Kriya Selected for FDA PreCheck Pilot Program Business Wire · 132d ago
- Lilly, Regeneron selected for US program to review new manufacturing plants faster, CNBC reports Reuters · 132d ago
- FDA to Expedite Review of Eli Lilly’s (LLY) New Manufacturing Facilities TipRanks · 132d ago
- Eli Lilly (LLY) Joins FDA PreCheck Pilot Program for Manufacturi GuruFocus · 132d ago
- Lilly, Regeneron selected for US program to review new manufacturing facilities faster, CNBC reports Yahoo · 132d ago
- A new FDA strategy aims to get medicines to the market faster Baton Rouge Business Report · 132d ago
- Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities CNBC · 132d ago
Topics
Related trends
RFK Jr.’s HHS Is Allowing These 6 Unapproved Peptides To Be Sold
Recent HHS policy changes under RFK Jr. allow the sale of six unapproved peptides, drawing attention from multiple outlets.
DEA And Marijuana Rescheduling Opponents File Final Briefs In Hearing Ahead Of Judge's Decision
Opposing sides file final briefs as a critical federal marijuana rescheduling hearing approaches a judge's decision.
Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B
Regulatory approvals for Hibsago mark the arrival of the first functional-cure therapy for chronic hepatitis B.
Exclusive | AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca reportedly made a $10 billion acquisition offer for obesity drugmaker Rhythm Pharmaceuticals.
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027—Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical reports third-quarter 2026 results while announcing major workforce reductions and pipeline cuts to target profitability.
Usona Files Psilocybin for Depression NDA as Race With Compass Tightens
Usona has filed a New Drug Application for its psilocybin depression treatment, intensifying the competitive race with Compass Pathways for FDA approval.